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The p27Kip1 tumor suppressor gene: Still a suspect or proven guilty?
The p27Kip1 cyclin-dependent kinase inhibitor is considered to be a tumor suppressor even though somatic mutations in 
p27Kip1 are only rarely detected in human tumors. On the other hand, overwhelming evidence indicates that its hemizygous 
or posttranscriptional loss plays an important role in tumorigenesis. Based on these data, p27Kip1 was classified as a hap-
loinsufficient tumor suppressor whose protein level has to be fine-tuned for optimal function. However, a recent study links 
germline mutations in p27Kip1 to multiple endocrine neoplasia syndrome in rats and humans, thus establishing p27Kip1 as 
a bona fide tumor suppressor gene.p27Kip1 was identified as a cell cycle 
inhibitor responsible for growth arrest 
induced by TGF-β and contact inhibition 
(Polyak et al., 1994). It belongs to the 
Cip/Kip family of cyclin-dependent kinase 
inhibitors (CKIs) together with p21Cip1 
and p57Kip2. Initially, p27 was thought 
to have an inhibitory effect against all 
cyclin-cdk complexes and was presumed 
to only negatively regulate cell cycle pro-
gression. Consistent with this, mice with 
homozygous deletion of the p27Kip1 
gene are larger compared to their wild-
type counterparts due to increased cell 
numbers in various organs, especially 
in the organs with normally high endog-
enous p27 levels (Sherr and Roberts, 
1999). In addition, p27-deficient mice 
develop pituitary tumors resembling the 
phenotype of Rb-deficient mice, con-
firming that the growth and tumor sup-
pressor function of p27 is mediated via 
its negative effect on the Rb pathway. 
Mice lacking one or both copies of p27 352	gene have increased susceptibility to car-
cinogen-induced tumorigenesis, but the 
wild-type p27 allele is always retained in 
these tumors formed in p27+/− animals, 
which has led to the conclusion that p27 
is a haploinsufficient tumor suppressor. 
Subsequent studies further supported 
this hypothesis, and they revealed that 
decreased, but not completely elimi-
nated, p27 protein levels could enhance 
tumorigenesis due to the positive effect 
of p27 on the assembly of cyclin D-cdk4 
complexes and thus on cell cycle pro-
gression (Sherr and Roberts, 1999). The 
dual function of p27 in the regulation of 
cell proliferation and tumorigenesis was 
convincingly demonstrated in an erbB2/
neu-induced mouse model of breast can-
cer in which heterozygous loss of p27 
accelerated but nullizygous loss inhibited 
tumor formation (Muraoka et al., 2002). 
Similar results were obtained in a Nkx3.1/
PTEN loss-induced prostate tumor model 
as well (Gao et al., 2004).Figure 1.	model	depicting	the	meN1-p27Kip1	tumor	suppressor	pathway
In	normal	cells	menin	is	part	of	a	protein	complex	responsible	for	histone	H3	lysine	4	methylation	(histone	
H3	K4met),	which	is	required	for	the	expression	of	p27Kip1	in	certain	cell	types,	including	endocrine	cells.	
In	meN1	syndrome,	due	to	mutation	in	either	menin	(menin*)	or	p27Kip1	(p27Kip1*)	cellular	p27Kip1	protein	
levels	decrease	resulting	in	tumor	formation.The regulation of p27 levels is fairly 
complex and predominantly occurs 
posttranscriptionally, involving phos-
phorylation by various kinases, ubiqui-
tin-mediated degradation, and nuclear 
export mechanisms (Koff, 2006). Since 
its discovery, p27 was presumed to be 
a tumor suppressor due to its growth-
inhibitory function, but despite compre-
hensive large-scale mutation screening 
studies in various human tumor types, 
genetic alterations in p27 have been 
infrequently detected. However, the pro-
tein level of p27 is decreased in most 
human tumors, and this correlates with 
worse clinical outcome in multiple can-
cer types, including breast, colon, and 
prostate cancer (Koff, 2006). Thus, it 
was concluded that the inactivation of 
p27 during tumorigenesis rarely involves 
genetic mechanisms.
However, a recent study by Pellegata 
et al. published in PNAS identified 
p27Kip1 as a gene responsible for mul-
tiple endocrine neoplasia-like (MENX) 
syndrome in rats (Pellegata et al., 2006). 
MENX is inherited in an autosomal 
recessive manner, and affected animals 
develop bilateral pheochromocytomas, 
parathyroid adenomas, multifocal thy-
roid C cell neoplasia, paragangliomas, 
and pancreatic islet cell tumors. Linkage 
analysis placed the responsible gene 
in a ?3 Mb area of rat chromosome 
4, and mutational analysis of candi-
date genes, including the Cdkn1b gene 
encoding p27Kip1, identified a homo-
zygous 8 nucleotide insertion in exon 2 
that leads to a frame shift after codon 
177 and a p27 protein with a different C 
terminus (p27_G177fs). Similar to p27−/− 
mice, rats homozygous for this germline 
mutation were larger compared to their 
wild-type littermates, and their life span 
was statistically significantly decreased. 
Heterozygous rats demonstrated the 
same phenotype as wild-types confirm-
ing the recessive inheritance of MENX. 
Immunohistochemical analyses of vari-
ous organs revealed extremely reduced cancer cell November	2006
	 p r e v i e w sor absent p27 protein levels in multiple 
organs in mut/mut animals, but this did 
not correlate with cellular proliferation, 
suggesting that p27 may have a CKI-
independent function in certain tissue 
types or not be required for the prolif-
eration of these cells. Indeed, the C-ter-
minal domain of p27 has been shown to 
be dispensable for cyclin-cdk complex 
binding and inhibition, and in some cell 
types p27 is involved in the regulation of 
Rac- or RhoA-dependent cell migration 
and Ras activation.
In humans, MEN syndromes are 
inherited in an autosomal dominant fash-
ion and are due to germline mutations 
in the MEN1 tumor suppressor gene 
(MEN1 syndrome) or the RET onco-
gene (MEN2A and MEN2B syndromes) 
(Marx, 2005). However, in ?30% of 
patients with MEN1 syndrome, muta-
tions in MEN1 could not be identified, 
but because genetic heterogeneity for 
the MEN1 phenotype was not expect-
ed, it was assumed that these patients 
were likely to still have a mutation in 
MEN1 that was not identifiable using 
currently employed methods. However, 
the rat MENX data raised the hypoth-
esis that p27Kip1 could be responsible 
for the MEN1 phenotype in a subset of 
these patients. Thus, Pellegata et al. 
sequenced the human CDKN1B gene in 
multiple members of a suspected MEN1 
family without an identifiable MEN1 
mutation. In an affected member of this 
family, a 48-year-old woman with a pitu-
itary tumor and primary hyperparathy-
roidism, a germline heterozygous TGG 
to TGA nonsense mutation at codon 76 
leading to a truncated p27 protein (p27_
W76X) was identified. This sequence 
alteration was not present in 380 healthy 
normal controls, thus it is unlikely to be a 
polymorphism. The same mutation was 
also detected in one of the patient’s 
sisters, who was diagnosed with renal 
angiomyolipoma, a nonendocrine tumor 
frequently observed in MEN1 families. 
Two out of four unaffected family mem-
bers analyzed were mutation negative, 
while two others were mutation carriers 
but symptom free, potentially due to their 
younger age. The proband’s father had 
acromegaly, and her brother died at age 
39 of hypertension, but blood samples 
were not available from these cases. 
Among all the tumors detected in the 
family members, only the renal angio-
myolipoma diagnosed in the proband’s 
older sister was available for molecu-
cancer cell November	2006	lar analysis. In this tumor the wild-type 
CDKN1B allele appeared to be main-
tained, and wild-type mRNA was detect-
ed, but the tumor cells demonstrated 
complete lack of p27 protein based on 
immunohistochemical analysis.
To address the potential mecha-
nism underlying the decreased p27 
levels and MEN phenotype in rats with 
the p27_G177fs and in humans with 
p27_W76X mutations, the authors exog-
enously expressed these proteins in rat 
fibroblasts and human MCF-7 and 293T 
cells together with wild-type and p27_
G177X (nonsense mutation at codon 
177 to determine if different C terminus 
influences function) controls and ana-
lyzed their levels and cellular localiza-
tion. Both p27_G177fs and p27_W76X 
were expressed at significantly lower 
levels compared to wild-type p27, and 
p27_W76X was only detected in the 
cytoplasm and thus could not function 
as a cdk inhibitor. It is not clear if p27_
W76X could act as a dominant nega-
tive and lead to the sequestration and 
downregulation of the wild-type protein, 
which could potentially explain the lack 
of p27 in tumors of heterozygous muta-
tion carriers.
The link between p27Kip1 and MEN1 
syndrome is not entirely surprising, since 
menin, encoded by the MEN1 gene, has 
been shown to participate in a complex 
that has histone H3 lysine 4 (H3K4) 
methylation activity in various human 
and mouse cells (Hughes et al., 2004). 
Furthermore, menin-dependent histone 
H3K4 methylation was required for the 
maintenance of p27 expression in pan-
creatic islet cells in MEN1+/− mice (Karnik 
et al., 2005). The histone H3K4 meth-
ylation promoting function of menin is 
thought to be required for its tumor-sup-
pressive function, since several patient-
derived mutants lost this activity.
The study by Pellagata et al. links 
genetic alterations in p27Kip1 to MEN 
syndrome in both rats and humans, sug-
gesting that p27 could be one of the key 
downstream targets of MEN1’s tumor-
suppressive function and germline 
or somatic mutations in p27Kip1 may 
play a role in a subset of MEN1 cases 
(Figure 1). However, several questions 
remain to be answered. To conclusively 
link the human p27_W76X mutation 
to MEN1 syndrome would require the 
analysis of more than one family and 
tumors that developed in the affected 
patients. Interestingly, the exact same truncating mutation (p27_W76X) was 
reported in one case of adult T cell leu-
kemia/lymphoma, but in this patient the 
mutation was reported to be somatic 
and accompanied with the loss of wild-
type allele in the tumor (Morosetti et 
al., 1995). Assuming that there are no 
technical issues, the lack of wild-type 
p27Kip1 allele loss in the heterozygous 
p27_W76X mutation carrier’s renal 
angiolipoma accompanied by the loss 
of p27 protein in the tumor cells requires 
some explanation and further mechanis-
tic studies. Most importantly, the possi-
bility that p27_W76X represents a rare 
allelic variant has to be eliminated by 
sequencing the complete coding region 
of p27Kip1 in a large number of controls 
to determine the frequency of all non-
sense mutations. However, regardless 
of these unresolved issues, p27Kip1 
has finally entered the stage of bona 
fide tumor suppressor genes, and these 
new results are likely to stimulate new 
waves of mutation screens in a subset 
of MEN syndrome cases and in sporadic 
endocrine tumors.
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